Gilead Sciences, Inc. (NASDAQ:GILD) Stock Rating Reaffirmed by Robert W. Baird
Robert W. Baird reiterated their outperform rating on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report sent to investors on Tuesday. Robert W. Baird currently has a $87.00 price target on the biopharmaceutical company’s stock.
Several other research firms have also recently commented on GILD. BidaskClub upgraded shares of Gilead Sciences from a sell rating to a hold rating in a research note on Monday, July 24th. Leerink Swann restated a hold rating and set a $74.00 target price on shares of Gilead Sciences in a report on Tuesday. BMO Capital Markets restated a hold rating and set a $72.00 target price on shares of Gilead Sciences in a report on Friday, July 21st. Vetr upgraded shares of Gilead Sciences from a buy rating to a strong-buy rating and set a $83.66 target price for the company in a report on Monday, June 26th. Finally, Zacks Investment Research downgraded shares of Gilead Sciences from a buy rating to a hold rating in a report on Tuesday, July 18th. Thirteen equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences presently has a consensus rating of Buy and an average target price of $80.33.
Shares of Gilead Sciences (NASDAQ:GILD) traded up 1.31% during midday trading on Tuesday, reaching $75.94. 8,954,646 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $69.98 and its 200 day moving average price is $68.63. The stock has a market capitalization of $99.18 billion, a P/E ratio of 8.25 and a beta of 1.21. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $82.10. Gilead Sciences also was the target of some unusual options trading activity on Wednesday. Stock investors purchased 23,892 put options on the stock. This represents an increase of approximately 241% compared to the average daily volume of 7,005 put options.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.11 by $0.45. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. Gilead Sciences’s quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.08 EPS. On average, equities analysts predict that Gilead Sciences will post $8.72 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (NASDAQ:GILD) Stock Rating Reaffirmed by Robert W. Baird” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://www.watchlistnews.com/gilead-sciences-inc-nasdaqgild-stock-rating-reaffirmed-by-robert-w-baird/1461839.html.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.74%. Gilead Sciences’s payout ratio is currently 22.58%.
In other news, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.06, for a total value of $355,300.00. Following the completion of the sale, the executive vice president now directly owns 102,988 shares of the company’s stock, valued at $7,318,327.28. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $71.00, for a total value of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares of the company’s stock, valued at $227,197,799. The disclosure for this sale can be found here. Insiders sold 128,276 shares of company stock valued at $9,190,610 over the last three months. 1.30% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. Hall Laurie J Trustee raised its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the last quarter. Cable Hill Partners LLC raised its position in Gilead Sciences by 51.9% in the first quarter. Cable Hill Partners LLC now owns 1,584 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 541 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its position in Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Finally, Penserra Capital Management LLC raised its position in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Institutional investors and hedge funds own 74.05% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.